Zhenfei Li
Key Laboratory Of Multi Cell Systems
Shanghai, 200031, China
Shanghai, 200031, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Fine structural design of 3βHSD1 inhibitors for prostate cancer therapy.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: June 25, 2025
Analysis of the transcriptomic and metabolomic landscape of prostate cancer with different anatomical origins using snFLARE-seq and mxFRIZNGRND.
Journal: Nature communications
Published: December 16, 2024
Epigenetic reader ZMYND11 noncanonical function restricts HNRNPA1-mediated stress granule formation and oncogenic activity.
Journal: Signal transduction and targeted therapy
Published: March 11, 2024
PRMT5-mediated FUBP1 methylation accelerates prostate cancer progression.
Journal: The Journal of clinical investigation
Published: August 22, 2023
Active DHEA uptake in the prostate gland correlates with aggressive prostate cancer.
Journal: The Journal of clinical investigation
Published: April 26, 2023
Prospective role of 3βHSD1 in prostate cancer precision medicine.
Journal: The Prostate
Published: December 15, 2022
Flexible solar cells based on foldable silicon wafers with blunted edges.
Journal: Nature
Published: August 24, 2022
The clinical efficacy and limitations of dutasteride-regulated abiraterone metabolism in abiraterone-resistant patients: a prospective single-arm clinical trial in Chinese patients.
Journal: Translational andrology and urology
Published: June 27, 2022
Celastrol recruits UBE3A to recognize and degrade the DNA binding domain of steroid receptors.
Journal: Oncogene
Published: April 29, 2022
Serum prolactin level as a predictive factor for abiraterone response in patients with metastatic castration-resistant prostate cancer.
Journal: The Prostate
Published: March 18, 2022
Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment.
Journal: Cell reports. Medicine
Published: December 08, 2021
Inhibiting 3βHSD1 to eliminate the oncogenic effects of progesterone in prostate cancer.
Journal: Cell reports. Medicine
Published: November 07, 2021
Last Updated: 09/26/2026